EGFR and non-small cell lung carcinoma: In approximately 40%–60% of Chinese patients with non-small cell lung cancer (NSCLC), mutations in the EGFR gene are present, enabling them to benefit from treatments involving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs).